ScripGene therapy-focused bluebird bio and its prospective buyers – private equity firms Carlyle and SK Capital Partners – are offering an additional option for bluebird shareholders to sell their stock, i
ScripAbeona Therapeutics obtained US Food and Drug Administration approval on 29 April for Zevaskyn, an autologous cell-based gene therapy for the ultra-rare connective tissue disorder recessive dystrophic
ScripAtsena Therapeutics thinks it can be a success story in the gene therapy field, where some companies have recently stumbled, with the closure of a funding round that it plans to use especially for its
ScripPfizer’s recent exit from gene therapies was not an indictment of the safety and efficacy of gene and cellular therapies. Rather it was the latest example of the difficulties in commercializing these